V. Bédoucha

发表

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study

W. Wiktor-Jedrzejczak, F. Giles, G. Saglio, 2017, Leukemia.

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

J. Radich, F. Giles, G. Saglio, 2018, Journal of Cancer Research and Clinical Oncology.

A Phase 3, Open-Label, Randomized Study of Asciminib, a STAMP Inhibitor, vs Bosutinib in CML After ≥2 Prior TKIs.

J. Cortes, M. Mauro, A. Hochhaus, 2021, Blood.

Long-term treatment-free remission (TFR) following frontline (1L) nilotinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom 144-wk results.

J. Radich, S. Acharyya, F. Giles, 2018 .

Combined therapy with saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed HIV‐infected protease inhibitor‐naive patients

M. Battegay, E. Bernasconi, C. Jaccard, 2001, HIV medicine.

Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

S. Kapoor, M. Mauro, A. Hochhaus, 2023, Leukemia.

Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks

S. Kapoor, J. Cortes, M. Mauro, 2021, Blood.

Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib: Results from the ENESTFreedom study.

J. Radich, W. Wiktor-Jedrzejczak, F. Giles, 2016 .

S155: EFFICACY AND SAFETY RESULTS FROM ASCEMBL, A PHASE 3 STUDY OF ASCIMINIB VS BOSUTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS: WK 96 UPDATE

M. Mauro, A. Hochhaus, N. Chaudhri, 2022, HemaSphere.

Effects of famotidine or an antacid preparation on the pharmacokinetics of nilotinib in healthy volunteers

W. Zhou, O. Yin, S. Novick, 2012, Cancer Chemotherapy and Pharmacology.